Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform.
The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia's core platform technology. Corresponding patents have also been granted in Europe and Japan, with additional applications pending in other major global jurisdictions.
U.S. Patent No. 12,502,408 relates to Minovia's proprietary mitochondrial augmentation technology for the treatment of primary mitochondrial diseases. The claims cover Minovia's lead program, MNV-201, which consists of autologous hematopoietic stem cells enriched with placental-derived mitochondria. MNV-201 is currently being evaluated in clinical trials for Pearson Syndrome and other severe genetic mitochondrial disorders.